![Renee T. Leck](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Renee T. Leck
Sociétés | Poste | Début | Fin |
---|---|---|---|
ORCHARD THERAPEUTICS PLC | Investor Relations Contact | - | - |
Historique de carrière de Renee T. Leck
Anciens postes connus de Renee T. Leck
Sociétés | Poste | Début | Fin |
---|---|---|---|
AGIOS PHARMACEUTICALS, INC. | Public Communications Contact | 01/05/2015 | 01/12/2018 |
Statistiques
Internationale
Etats-Unis | 2 |
Royaume-Uni | 2 |
Opérationnelle
Public Communications Contact | 1 |
Investor Relations Contact | 1 |
Sectorielle
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
AGIOS PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Orchard Therapeutics Plc
![]() Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Renee T. Leck
- Expérience